- Home
- USEA vs CLRB Comparison
USEA vs CLRB Comparison
Compare USEA & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- CLRB
- Stock Information
- Founded
- USEA 2004
- CLRB 2002
- Country
- USEA Greece
- CLRB United States
- Employees
- USEA N/A
- CLRB N/A
- Industry
- USEA Marine Transportation
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- USEA Consumer Discretionary
- CLRB Health Care
- Exchange
- USEA Nasdaq
- CLRB Nasdaq
- Market Cap
- USEA 15.6M
- CLRB 14.2M
- IPO Year
- USEA N/A
- CLRB N/A
- Fundamental
- Price
- USEA $1.70
- CLRB $5.08
- Analyst Decision
- USEA
- CLRB Hold
- Analyst Count
- USEA 0
- CLRB 2
- Target Price
- USEA N/A
- CLRB N/A
- AVG Volume (30 Days)
- USEA 22.5K
- CLRB 129.4K
- Earning Date
- USEA 08-06-2025
- CLRB 08-14-2025
- Dividend Yield
- USEA 2.35%
- CLRB N/A
- EPS Growth
- USEA N/A
- CLRB N/A
- EPS
- USEA N/A
- CLRB N/A
- Revenue
- USEA $42,625,000.00
- CLRB N/A
- Revenue This Year
- USEA N/A
- CLRB N/A
- Revenue Next Year
- USEA N/A
- CLRB N/A
- P/E Ratio
- USEA N/A
- CLRB N/A
- Revenue Growth
- USEA N/A
- CLRB N/A
- 52 Week Low
- USEA $1.00
- CLRB $4.11
- 52 Week High
- USEA $2.78
- CLRB $67.50
- Technical
- Relative Strength Index (RSI)
- USEA 61.69
- CLRB 52.18
- Support Level
- USEA $1.66
- CLRB $4.82
- Resistance Level
- USEA $1.78
- CLRB $5.34
- Average True Range (ATR)
- USEA 0.05
- CLRB 0.37
- MACD
- USEA 0.00
- CLRB 0.09
- Stochastic Oscillator
- USEA 63.64
- CLRB 71.43
About USEA United Maritime Corporation
United Maritime Corp is an international shipping company. It is engaged in seaborne transportation services. The group currently operates a fleet of seven dry bulk vessels, comprising three Panamax, two Capesize and two Kamsarmax vessels with an aggregate cargo-carrying capacity of approximately 750,758 dwt.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.